PFE (US)


January 15, 2026

Trump’s Great Healthcare Plan – We’ve Seen and Heard It Before

By Beth Steindecker

President Trump’s long-teased “Great Healthcare Plan”, released this morning, does little to meaningfully move the needle on healthcare redesign or cost containment beyond our prior expectations for legislative action affecting Obamacare insurers, non-ACA managed care…

Read More >>

October 6, 2025

Capitol Policy Weekly: Government Shutdown, Farmer Aid and Drug Pricing

By Joe Lieber

While the government shutdown is the top issue in Washington this week, we could also expect: 1) positive news out of the White House on aid for farmers, which is likely positive for the farm…

Read More >>

September 10, 2025

Rx Advertising: Policy Quick Take

By John Leppard

While we can at this point give no better than tossup odds to FDA plans to curtail direct-to-consumer (DTC) drug advertisements surviving inevitable legal challenges, we caution that the enforcement approach outlined by the agency…

Read More >>

June 18, 2025

Rx Advertisements & RFK: Legal Guardrails

By John Leppard

Amid reports that HHS is considering steps to curtail direct-to-consumer (DTC) drug advertisements – with negative implications for high spenders in this area [ABBV, NVO, REGN] – we see significant impediments to how far /…

Read More >>

November 15, 2024

RFK to HHS: Biopharma / Lifesciences Smoke or Fire?

By John Leppard

Key Takeaways: We are initially skeptical that Trump’s selection of Robert F. Kennedy Jr. (RFK) to lead HHS can survive Senate confirmation but, if we are wrong, would note that any HHS secretary is constrained…

Read More >>